You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

peripheral T-cell lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma Trial in Xiamen (Chidamide combined

Recruiting
  • Peripheral T Cell Lymphoma
  • +2 more
  • Chidamide combined with Duvillisib
  • Xiamen, Fujian, China
    The First Affiliated Hosptial of Xiamen University
Nov 28, 2023

Peripheral T-cell Lymphoma Trial (Linperlisib in combination with CHOP)

Not yet recruiting
  • Peripheral T-cell Lymphoma
  • Linperlisib in combination with CHOP
  • (no location specified)
Jul 10, 2023

Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Trial (GFH009)

Not yet recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
  • (no location specified)
Jun 28, 2023

Newly Diagnosed Peripheral T-cell Lymphoma Trial in Wuhan (Duvelisib, Chidamide)

Recruiting
  • Newly Diagnosed Peripheral T-cell Lymphoma
  • Duvelisib, Chidamide
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Jul 27, 2023

Newly Diagnosed Peripheral T-cell Lymphoma Trial in Nanjing (CMOP+Chidamide)

Recruiting
  • Newly Diagnosed Peripheral T-cell Lymphoma
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
Jun 1, 2023

Peripheral T Cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

Recruiting
  • Peripheral T Cell Lymphoma
  • Linperlisib in combined with Chidamide
  • Beijing, Beijing/China, China
  • +1 more
Oct 9, 2023

Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,

Recruiting
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Angioimmunoblastic T-cell Lymphoma
  • Changchun, Jilin, China
    The First Bethune Hospital of Jilin University
Apr 7, 2023

Circulating Tumor DNA Sequencing in Peripheral T-cell Lymphomas

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • circulating tumoral DNA detection
  • Rouen, France
    Centre Henri Becquerel
Oct 13, 2023

Peripheral T Cell Lymphoma Trial in Shandong, Shanghai, Sichuan (84-gene penal)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • 84-gene penal
  • Shandong, China
  • +2 more
Jul 6, 2023

Minimal Residual Disease in Peripheral T-cell Lymphoma

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Tumor biopsy
  • +2 more
  • Boston, Massachusetts
  • +2 more
Dec 19, 2022

Relapsed or Refractory Peripheral T-cell Lymphoma Trial in Taiwan (Chidamide)

Not yet recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma
  • Kaohsiung, Taiwan
  • +4 more
Apr 17, 2023

Peripheral T Cell Lymphoma Trial in Zhengzhou (SHR0302)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • Zhengzhou, Henan, China
    Henan cancer hospital
Jun 2, 2023

Peripheral T Cell Lymphoma Trial in Duarte, Aurora, Philadelphia (Nivolumab and EPOCH)

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Nivolumab and EPOCH
  • Duarte, California
  • +2 more
Jan 6, 2023

Peripheral T Cell Lymphoma Trial (CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • (no location specified)
Dec 29, 2022

Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • CAR-T Therapy
  • Hefei, Anhui, China
  • +7 more
Jul 31, 2023

Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype Trial in Guangzhou (Chidamide combined with CHOP,

Recruiting
  • Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
  • Guangzhou, Guangdong, China
    Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
Oct 7, 2022

Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Pediatric Hodgkin Lymphoma
  • Brentuximab Vedotin (Genetical Recombination)
  • Tokyo, Japan
    Takeda Selected Site
Oct 11, 2022

Peripheral T-cell Lymphoma Trial in Beijing (AK104)

Terminated
  • Peripheral T-cell Lymphoma
  • AK104
  • Beijing, Beiing, China
    Beijing Cancer Hospital
Oct 17, 2022

Previously Untreated Peripheral T-cell Lymphoma Trial in Tampa, Saint Louis, New York (CC-486 Administration, CHOP

Active, not recruiting
Has Results
  • Previously Untreated Peripheral T-cell Lymphoma
  • CC-486 Administration
  • CHOP Administration
  • Tampa, Florida
  • +3 more
Jan 18, 2023

T-cell Lymphoma Patients After First-line Treatment Failure Trial (SHR2554; Chidamide analog tablets, SHR2554 analog tablets;

Not yet recruiting
  • T-cell Lymphoma Patients After First-line Treatment Failure
  • SHR2554; Chidamide analog tablets
  • SHR2554 analog tablets; Chidamide
  • (no location specified)
Nov 5, 2023

Peripheral T Cell Lymphoma Trial in Shanghai (Azacitidine Injection, Dasatinib, Linperlisib)

Recruiting
  • Peripheral T Cell Lymphoma
  • Azacitidine Injection
  • +6 more
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Nov 8, 2022

Remitoro in Recurrent or Refractory Peripheral T Cell Lymphoma

Recruiting
  • Lymphoma, T-cell, Peripheral
  • Lymphoma, T-cell, Cutaneous
  • Nagoya, Japan
  • +2 more
Nov 24, 2022

Peripheral T-cell Lymphoma Targeted Therapy Trial in Tianjin (Azacitidine, Chidamide, Cyclophosphamide)

Enrolling by invitation
  • Peripheral T-cell Lymphoma Targeted Therapy
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Insititute & Hospital
Jan 9, 2023

Peripheral T Cell Lymphoma Trial in Zhengzhou (Golidocitinib, CHOP Regimen)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jul 18, 2023

Peripheral T Cell Lymphoma, Epigenetic Repression Trial in Tianjin (Chidamide, Azacitidine)

Recruiting
  • Peripheral T Cell Lymphoma
  • Epigenetic Repression
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jul 14, 2023